Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

Cancer Cell

Volumn 21, Issue 4, 2012, Pages 577-592

  Zhang, Bin ^a   Ho, Yin Wei ^a   Huang, Qin ^a   Maeda, Takahiro ^a   Lin, Allen ^a   Lee, Sung uk ^a   Hair, Alan ^b   Holyoake, Tessa L ^b   Huettner, Claudia ^c   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CD150 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCL3 CHEMOKINE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL CYCLE; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR MICROENVIRONMENT;

MUS MUSCULUS;

EID: 84859832491     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.02.018     Document Type: Article

References (43)

1. Akala O.O., Park I.K., Qian D., Pihalja M., Becker M.W., Clarke M.F. Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature 2008, 453:228-232.
2. Akashi K., Traver D., Miyamoto T., Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000, 404:193-197.
3. Bhatia R., McGlave P.B., Dewald G.W., Blazar B.R., Verfaillie C.M. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995, 85:3636-3645.
4. Bonig H., Priestley G.V., Papayannopoulou T. Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood 2006, 107:79-86.
5. Cappella P., Gasparri F., Pulici M., Moll J. Cell proliferation method: click chemistry based on BrdU coupling for multiplex antibody staining. Curr. Protoc. Cytom. 2008, Chapter 7:Unit7.34.
6. Cashman J.D., Eaves C.J., Sarris A.H., Eaves A.C. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998, 92:2338-2344.
7. Cashman J., Clark-Lewis I., Eaves A., Eaves C. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood 2002, 99:792-799.
8. Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 2010, 70:3402-3410.
9. Chomel J.C., Bonnet M.L., Sorel N., Bertrand A., Meunier M.C., Fichelson S., Melkus M., Bennaceur-Griscelli A., Guilhot F., Turhan A.G. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011, 118:3657-3660.
10. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121:396-409.
11. Cortes J., Hochhaus A., Hughes T., Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol. 2011, 29:524-531.
12. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417. IRIS Investigators.
13. Eaves C.J., Cashman J.D., Wolpe S.D., Eaves A.C. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc. Natl. Acad. Sci. USA 1993, 90:12015-12019.
14. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1977, 63:125-130.
15. Graham S.M., Jørgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
16. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002, 99:3792-3800.
17. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351:657-667.
18. Järås M., Johnels P., Hansen N., Agerstam H., Tsapogas P., Rissler M., Lassen C., Olofsson T., Bjerrum O.W., Richter J., Fioretos T. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. USA 2010, 107:16280-16285.
19. Jin L., Tabe Y., Konoplev S., Xu Y., Leysath C.E., Lu H., Kimura S., Ohsaka A., Rios M.B., Calvert L., et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 2008, 7:48-58.
20. Jordan C.T., Yamasaki G., Minamoto D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp. Hematol. 1996, 24:1347-1355.
21. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., Moiraghi B., Shen Z., Mayer J., Pasquini R., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2260-2270.
22. Kiel M.J., Yilmaz O.H., Iwashita T., Yilmaz O.H., Terhorst C., Morrison S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005, 121:1109-1121.
23. Kondo M., Weissman I.L., Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997, 91:661-672.
24. Koschmieder S., Göttgens B., Zhang P., Iwasaki-Arai J., Akashi K., Kutok J.L., Dayaram T., Geary K., Green A.R., Tenen D.G., Huettner C.S. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005, 105:324-334.
25. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 2006, 12:1175-1180.
26. Li S., Ilaria R.L., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 1999, 189:1399-1412.
27. Mahon F.X., Réa D., Guilhot J., Guilhot F., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035. Intergroupe Français des Leucémies Myéloïdes Chroniques.
28. Månsson R., Hultquist A., Luc S., Yang L., Anderson K., Kharazi S., Al-Hashmi S., Liuba K., Thorén L., Adolfsson J., et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 2007, 26:407-419.
29. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
30. Mihara K., Imai C., Coustan-Smith E., Dome J.S., Dominici M., Vanin E., Campana D. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br. J. Haematol. 2003, 120:846-849.
31. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998, 92:3780-3792.
32. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
33. Peled A., Hardan I., Trakhtenbrot L., Gur E., Magid M., Darash-Yahana M., Cohen N., Grabovsky V., Franitza S., Kollet O., et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002, 20:259-266.
34. Peng H., Erdmann N., Whitney N., Dou H., Gorantla S., Gendelman H.E., Ghorpade A., Zheng J. HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia 2006, 54:619-629.
35. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 2010, 120:2254-2264.
36. Petzer A.L., Eaves C.J., Lansdorp P.M., Ponchio L., Barnett M.J., Eaves A.C. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996, 88:2162-2171.
37. Reynaud D., Pietras E., Barry-Holson K., Mir A., Binnewies M., Jeanne M., Sala-Torra O., Radich J.P., Passegué E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20:661-673.
38. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259. ENESTnd Investigators.
39. Sarry J.E., Murphy K., Perry R., Sanchez P.V., Secreto A., Keefer C., Swider C.R., Strzelecki A.C., Cavelier C., Récher C., et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J. Clin. Invest. 2011, 121:384-395.
40. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340:1330-1340.
41. Schemionek M., Elling C., Steidl U., Bäumer N., Hamilton A., Spieker T., Göthert J.R., Stehling M., Wagers A., Huettner C.S., et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010, 115:3185-3195.
42. Verfaillie C.M., McCarthy J.B., McGlave P.B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest. 1992, 90:1232-1241.
43. Zhang Q., Guo R., Schwarz E.M., Boyce B.F., Xing L. TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res. Ther. 2008, 10:R37.